Mineralys Therapeutics (MLYS) insider plans sale of 417 shares in Form 144

Rhea-AI Filing Summary

Mineralys Therapeutics insider David Rodman has filed a Form 144 notice to sell common stock. The filing covers 417 shares of Mineralys Therapeutics, Inc. common stock to be sold through Merrill Lynch on or about February 17, 2026 on the NASDAQ market, with an aggregate market value of $11,505.03.

The 417 shares were acquired the same day through the exercise of employee stock options via a broker-assisted cashless exercise. The notice also lists prior sales of Mineralys common stock by David Rodman over the past three months, including 192,715 shares sold on January 5, 2026 for gross proceeds of $6,749,100.06 and 70,037 shares sold on January 2, 2026 for $2,511,919.03.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	417	11505.03	79139956	02/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	02/17/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			417	02/17/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/05/2026	192715	6749100.06
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/02/2026	70037	2511919.03
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/09/2026	2170	72195.90
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/12/2026	6348	205142.99
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/13/2026	7709	252469.75
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/14/2026	11367	370645.39
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	01/20/2026	416	13353.60
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/09/2026	2171	65585.91
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/12/2026	6349	184076.52
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/16/2026	14055	385732.29

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for MLYS disclose about planned stock sales?

The Form 144 discloses that David Rodman plans to sell 417 shares of Mineralys Therapeutics, Inc. common stock. These shares are to be sold through Merrill Lynch on or about February 17, 2026 on the NASDAQ exchange, with an aggregate market value of $11,505.03.

How were the 417 MLYS shares in the Form 144 acquired?

The 417 Mineralys Therapeutics shares were acquired on February 17, 2026 through the exercise of employee stock options. The transaction used a broker-assisted cashless exercise, meaning the broker handled share sales needed to cover the exercise price and related costs on that same date.

What recent MLYS stock sales by David Rodman are listed in the Form 144?

The filing lists several Mineralys Therapeutics common stock sales by David Rodman in the past three months. These include 192,715 shares sold on January 5, 2026 for $6,749,100.06 and 70,037 shares sold on January 2, 2026 for $2,511,919.03, along with multiple smaller transactions.

Which broker and exchange are involved in the MLYS Form 144 planned sale?

The planned sale of 417 Mineralys Therapeutics common shares will be handled by Merrill Lynch. The filing states that trades are expected to occur on the NASDAQ exchange, with the approximate sale date given as February 17, 2026 for this particular transaction.

What does the Form 144 say about the seller’s knowledge of MLYS information?

By signing the Form 144, the seller represents that they do not know any material adverse, non-public information about Mineralys Therapeutics’ current or prospective operations. This representation is required as part of the form’s certification and is highlighted in the signature section language.